Loading cancer entity…
Loading cancer entity…
Variants & evidence
1 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| RAD50 L1237F1 | ||||||||
| Checkpoint Kinase Inhibitor AZD7762 + IrinotecanCombination | Ureter Small Cell Neuroendocrine CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID5829A 51-year-old woman with an invasive small-cell cancer of the ureter showed a durable complete response at 3-years when treated with AZD7762 (an ATP-competitive checkpoint kinase inhibitor) and irinot… (full text at CIViC) PMID 24934408 · Al-Ahmadie et al., 2014 · Open in CIViC | civic |
Data updated 23 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.